Atrium Therapeutics, Inc.
RNA
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -123.29% | -153.09% | |||
| Total Depreciation and Amortization | 184.91% | 110.34% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 931.12% | -37.66% | |||
| Change in Net Operating Assets | -457.31% | 278.38% | |||
| Cash from Operations | -180.49% | -132.99% | |||
| Capital Expenditure | -- | -303.21% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | -- | -303.21% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | 2,615.53% | 137.37% | |||
| Cash from Financing | 2,615.53% | 137.37% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -- | -- | |||